Clinical Trial Update: Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating docetaxel plus carboplatin and anlotinib as first-line therapy for non-small cell lung cancer is ongoing, with status curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Tongji Hospital | Conditions: NSCLC | Phase 4 | Status: UNKNOWN